Saebo

Saebo

Growth Stage

No Plateau In Sight.

No Plateau In Sight.

Overview

Raised this Round: Raised: $600,188

Total Commitments ($USD)

Platform

StartEngine

Start Date

12/31/2020

Close Date

05/31/2022

Min. Goal
$10,000
Max. Goal
$1,069,999
Min. Investment

$248

Security Type

Equity - Common

Series

Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$0.50

Early Bird Valuation

$8,771,510

Pre-Money Valuation

$10,964,388

Year Founded

2004

Industry

Consumer Products, Goods & Services

Tech Sector

Medtech

Distribution Model

B2B/B2C

Margin

High

Capital Intensity

High

Location

Charlotte, North Carolina

Business Type

Growth

Saebo, with a pre-money valuation of $11 million, is raising crowdfunding on StartEngine. The company rehabilitation products for stroke survivors. The mobility solutions help patients overcome paralysis, maximize neurological recovery, and regain quality of life. Henry Hoffman founded Saebo in 2004. The current crowdfunding round has a minimum target of $10,000 and a maximum target of $1,069,999, and the funds will be used to expand into adjacent markets, including orthotic rehabilitation, diabetic neuropathy, and non-opioid pain management. Saebo has a proven track record with 17 patents, a network across six continents and 40 countries, and $44 million in revenue to date.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$4,444,270

$4,470,674

COGS

$1,783,145

$1,801,561

Tax

$0

$0

 

 

Net Income

$-1,195,857

$-992,477

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$25,660

$90,733

Accounts Receivable

$401,583

$344,826

Total Assets

$1,371,954

$1,382,393

Short-Term Debt

$1,007,162

$957,804

Long-Term Debt

$7,975,603

$6,754,518

Total Liabilities

$8,982,765

$7,712,322

Financials as of: 12/31/2020
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Analyst Report Analyst Report Methodology Article

Synopsis

In the United States, stroke accounts for the leading cause of serious long term disability. Over half of all stroke survivors 65 and older experience a loss of mobility at some point after their diagnosis. This mobility loss can include difficulty walking or driving, the inability to unclench a fist or unbend an arm, dizziness or balance issues, and general coordination problems. As many as 40% of stroke patients suffer from impairments for the rest of their lives.

Saebo offers rehabilitation products for individuals who have suffered a stroke and are attempting to get movement back in some part of their body.  The company has developed a suite of products to help patients regain mobility and dexterity as well as prevent further injury during the healing process. Some products are static wearables — like gloves and splints — that help patients regain strength and control. Other Saebo offerings use low level electrical stimulation to trigger muscle movements and nerve regeneration. Saebo is also incorporating the use of VR as a therapeutic aid. 

Saebo’s current StartEngine raise has been rated a Neutral Deal by the KingsCrowd investment team.

Next Section: Price

Price

Saebo is raising at a $10.9 million valuation. Although this may seem like a reasonable price for a medtech company, it is not justified by the company’s current revenue figures. Thus, Saebo’s price score is its lowest.

Next Section: Market

Market

The global stroke management market was valued at more than $22 billion in 2016. It is projected to rise to nearly $37 billion by 2023 as the prevalence of strokes continues to rise, particularly in young adults. The market seems large, but a problem for Saebo is that the majority of the costs associated with strokes is from diagnostics — not therapeutics. Given that Saebo’s products sit on the therapy side of the industry, the company’s actual addressable market is much more niche in nature. Balancing these facts together, the market score for Saebo is below average.

Next Section: Team

Team

Saebo lists Henry Hoffman as its co-founder and president — though no other co-founder is listed on the raise page. Prior to founding Saebo, Hoffman worked at Burke Rehabilitation Hospital as an occupational therapist and clinical specialist. His specialization was in manual therapy and neurorehabilitation. Hoffman has been working in the field of occupational therapy for stroke victims for the last 22 years. He also holds more than 15 patents for various therapeutic medical splints and devices. 

Hoffman is joined by a finance team with a wealth of experience in their respective areas. Executive Chairman Todd Wiebusch has 30 years’ experience as a healthcare investor at CHMG Capital, LLC, an investment firm that focuses on healthcare companies in the southeastern US. Similarly, Saebo’s VP of Finance, Alan Zdyb, has worked for nearly 20 years at CHMG Capital. It’s worth noting that neither Wiebusch or Zdyb are fully dedicated to Saebo at this time — both still work at CHMG Capital as well.

Christopher Klett acts as Saebo’s Chief Operating Officer. Although his LinkedIn page only lists his position at Saebo, his bio on the company’s raise page states that previously he worked as the Director of Mergers and Acquisitions at CHMG Capital. Lastly, Saebo has also assembled an experienced team of medical specialists who fulfill various roles. 

Co-founder Hoffman has strong medical experience and multiple patents. However, Wiebusch, Zdyb, and Klett all come from a medical investment background, which does not necessarily lend itself to running a medical products company. Taken all together, Saebo’s team score is just below average.

Next Section: Differentiators

Differentiators

Saebo’s product allows for in-home use, which means that users can continue their physical therapy remedies with top-of-the-line equipment not only at PT appointments, but from their own homes as well. This makes accessibility to quality care much easier, as patients no longer need to worry about putting their recovery on hold when they leave the hospital. It also helps patients cut down the costs of excess appointments (which may or may not be covered by insurance — long term coverage for strokes can be confusing and frustrating). 

Saebo is not alone in offering at-home rehabilitation equipment to stroke survivors. Competitor Neofect offers similar smart glove and hand brace equipment, and mirror boxes can be purchased on Amazon. However, Saebo has built a broader range of therapeutic equipment than many of its competitors, and its pricing looks to be on par or cheaper in many instances. The company has also secured 17 patents, which greatly increases its defensibility. Due to all these factors, the differentiators score for Saebo is its strongest across all five metrics.

Next Section: Performance

Performance

Saebo has been around since 2004 and has seen a total of $44 million in revenue over its lifetime. In 2018 and 2019, the revenue stayed steady at $4.7 and $4.4 million, respectively. The company does have sizable debt, with just about $8 million in long term and slightly under $1 million in the short term. Saebo’s net income was -$1.2 million in 2019.

In terms of non-financial performance, there is much to be happy about with Saebo. The company has sold nearly 100,000 at-home products and operates its business around the world. Its products (in this instance, the SaeboFlex) have been proven to have positive effects on patients, including a notable increase in grip strength.

Given Saebo’s strong revenue and fully developed products, its performance score is above average.

Next Section: Bearish Outlook

Bearish Outlook

Saebo was founded in 2004 and has yet to grow into a profitable business. Its product is solid, but it has been unable to leverage its successes into a net income for the company. Additionally, the Saebo team does not have strong experience with manufacturing or supplying medtech products. Relevant medical experience and expertise in healthcare investing does not necessarily translate into the successful operation of a product-focused business.

Next Section: Bullish Outlook

Bullish Outlook

The promising nature of Saebo is almost entirely in its product. The SaeboFlex has had studies done on it, proving its efficacy. It’s so noteworthy that it has been put on display in the London Science Museum as a part of its Medicine Galleries exhibit. The product works and is top of the line — which certainly could indicate future success for Saebo. The company has also managed to complete sales around the world, with the SaeboFlex alone being sold in more than 50 countries. This global traction greatly increases the available market for Saebo and could be the key to profitability in the future.

Next Section: Executive Summary

Executive Summary

Saebo provides well designed products aimed at allowing stroke victims to regain movement in areas of their body. The products are proven to be effective, and the company has completed sales around the world. Over 17 years of operations, Saebo has earned $44 million in total revenue and gained multiple patents.

However, the company is still running at a net loss. Promising tech and good reviews evidently haven’t been parlayed into a profitable business — and when considering the viability of investment, the profitability of the company is an important metric. It is also unclear if the current team has the proper expertise to move Saebo forward. Balancing the company’s strong product offering against profitability and operational concerns, Saebo is a Neutral Deal at this time.

For questions regarding the KingsCrowd staff pick or ratings for this company, please reach out to support@kingscrowd.com

Analysis written by Ethan Thomas.

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Saebo on StartEngine
Platform: StartEngine
Security Type: Equity - Common
Valuation: $10,964,388
Price per Share: $0.50

Follow company

Follow Saebo on StartEngine

Buy Saebo's Deal Report

Warning: according to the close date for this deal, Saebo may no longer be accepting investments.

Saebo Deal Report

Get KingsCrowd’s comprehensive report on Saebo including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Saebo is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the Saebo deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge